Phase 1/2Completed
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Dasatinib and Quercetin, a Combination of Senolytics to Treat Fibrotic Non-alcoholic Fatty Liver Disease - the TRUTH Study
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Academic or other)
- Enrolment
- 30 enrolled
- Conditions
- NAFLD; NASH With Fibrosis; Liver Fibrosis
- Interventions
- Dasatinib 100 MG + Quercetin (1000 MG); Placebo
- Ages
- adults, older adults
- Registry
- NCT05506488
From the registry
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
Primary outcomes
- The primary endpoint is the binary outcome improvement of fibrosis with at least 1-point without worsening of fibrosis and NAFLD score based on histology after 21 weeks (yes/no). Individuals will be labeled as responder or non-responder.